AnaptysBio (NASDAQ:ANAB) Issues Quarterly Earnings Results

AnaptysBio (NASDAQ:ANAB) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($1.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58, Zacks reports. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%.

AnaptysBio Stock Performance

NASDAQ ANAB traded down $0.72 during trading hours on Thursday, hitting $21.49. The company had a trading volume of 537,244 shares, compared to its average volume of 347,985. The business has a 50 day moving average of $33.00 and a 200-day moving average of $29.83. AnaptysBio has a 1-year low of $13.36 and a 1-year high of $41.31. The company has a market cap of $589.56 million, a PE ratio of -3.38 and a beta of -0.24.

Analysts Set New Price Targets

ANAB has been the subject of several analyst reports. JPMorgan Chase & Co. increased their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Wedbush reiterated an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a report on Wednesday. UBS Group boosted their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Truist Financial lifted their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Finally, Guggenheim increased their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $55.45.

Insider Buying and Selling at AnaptysBio

In related news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the transaction, the insider now directly owns 15,398 shares of the company’s stock, valued at $595,440.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The shares were acquired at an average cost of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the transaction, the insider now owns 7,794,996 shares in the company, valued at $284,517,354. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is owned by insiders.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.